"drug-controller-general-of-india-dcgi"

New Delhi: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) is expected to meet on Tuesday afternoon to discuss Bharat Biotech’s application for clinical trials of its intranasal Covid vaccine as a booster or a third dose. The Hyderabad-based manufacturer has proposed the booster dose for those who have been […]

Hyderabad: Hyderabad-based Hetero, a vertically integrated pharmaceutical organisation, has received Drug Controller General of India (DCGI) nod for manufacture and marketing of molnupiravir capsules 200 mg (Movfor). Molnupiravir is an oral antiviral indicated for restricted emergency use in India to treat adult patients with Covid-19. Hetero’s Movfor will be made available in a 40 capsule […]

The collaboration between IICT and Lee Pharma is expected to provide alternatives of cheaper therapeutics against Covid-19.

The Pune-based firm has also sought approval for test analysis and examination.

The clinical trials will be performed on more than 2,400 subjects suffering from mild to moderate Covid-19, across over 40 sites in India

The drug firm over the past few weeks has ramped up supply of multiple medicines including Remdesivir to meet the surge in demand.

These three species are now listed as Critically Endangered by the IUCN, the highest threat category ahead of extinction.